March 4, 2014
Canterbury, UK – 4 March 2014 – Creabilis, a late clinical stage European dermatology company with a focus on pruritus (itch), today announces the publication of new results showing pruritus severity in psoriasis patients is not correlated with psoriasis disease severity in a letter to the Journal of the American Academy of Dermatology (JAAD).
The letter was authored by Drs David Roblin and Ro Wickramasinghe of Creabilis and Creabilis Scientific Advisory Board member, Professor Gil Yosipovitch, Chair of the Department of Dermatology and Director of the Temple Itch Center at Temple University School of Medicine. 
An analysis of data drawn from Creabilis’ Phase 2b study of its lead product candidate CT327 in psoriasis patients showed no clinically meaningful correlation between pruritus severity and psoriasis disease severity in patients at baseline (The letter can be found online at: http://www.jaad.org/article/S0190-9622(13)01012-8/fulltext).
Dr David Roblin, CMO of Creabilis said: “Pruritus has a significant impact on the quality of life of psoriatic patients. In a recent study 80% of psoriatics reported it as the most important and severe symptom. The analysis we have presented in JAAD suggests that treating these patients that have pruritus with anti-inflammatory agents may not always be the best approach to addressing this symptom. Attention should be paid to the development of targeted anti-pruritic therapies for patients with pruritus associated with psoriasis and other dermatological conditions.” Roblin et al (2014). Pruritus severity in patients with psoriasis is not correlated with psoriasis disease severity. J Am Acad Dermatol. 2014 Feb;70(2):390-1 (doi: 10.1016/j.jaad.2013.09.030)